1. Title 21 Code of Federal Regulations Section 314.3.
2. Guidance for Industry:bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. December2013.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377465.pdf. Accessed December 17 2018.
3. Novel bioequivalence approach for narrow therapeutic index drugs
4. Draft guidance on warfarin sodium. December 2012.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201283.pdf. Accessed December 17 2018.
5. Draft guidance on phenytoin sodium extended release capsule.December 2014.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428265.pdf. Accessed December 17 2018.